Posted by Michael Wonder on 04 Jul 2021
Medicare ‘coverage with evidence development’ for aducanumab? How might it work?
30 June 2021 - In the wake of the FDA’s controversial decision to approve aducanumab for Alzheimer’s disease, how will, and how should, Medicare respond?
We propose a coverage with evidence development option for the Centers for Medicare and Medicaid Services, and we examine how the agency’s past decisions on high-price technology may offer a guide.
